



## **Market Data**

## Nexalin Technology, Inc. Nasdaq: NXL

| Fiscal Year        | Dec. 31 |
|--------------------|---------|
| Price              | \$1.16  |
| Market Cap         | \$8.6M  |
| Shares Out.        | 7.4M    |
| Float              | 5.7M    |
| Avg. Vol. (90-day) | 582,307 |
| Revenue (ttm)      | \$0.1M  |
| Cash (mrq)         | \$3.0M  |
|                    |         |

Price & share data as of May 9, 2024

#### Auditor: Marcum LLP

Legal Counsel: Warshaw Burstein LLP

Transfer Agent: Continental Stock Transfer & Trust

# nexalin.com



Gen-3 Headset

Nexalin uses proprietary single-use electrodes to deliver an undetectable proprietary frequency-based waveform with lifetime recurring revenue.

## **Company Overview**

Nexalin Technology is a pioneering medical technology company focused on addressing the global mental health crisis through innovative neurostimulation devices. Nexalin's products, which include the Gen-2 and newly introduced Gen-3 HALO<sup>™</sup> Clarity devices, are non-invasive and utilize advanced frequency-based stimulation to target deep brain structures associated with various mental health disorders. These disorders include but are not limited to depression, anxiety, insomnia, PTSD, and traumatic brain injuries. Nexalin's commitment to nonpharmacological treatment options is underpinned by extensive clinical research and intellectual property protections, aiming to provide significant therapeutic benefits without adverse effects. The company's approach integrates product innovation with a virtual clinic model to enhance accessibility and effectiveness of treatments, offering a significant step forward in mental healthcare.

# **Investment Highlights**

### Innovative technology with proven clinical results

- Pioneering non-invasive, frequency-based deep brain stimulation devices targeting treatment-resistant mental health disorders including PTSD, insomnia, depression, and more
- Demonstrated improvements in sleep quality and mental health parameters, substantiated by multiple peer-reviewed studies
- Positive outcomes from studies conducted at University of California, San Diego showing effectiveness in reducing PTSD and post-concussive symptoms

## Strategically positioned to address massive market opportunity

- Mental health market projected to reach \$537 billion by 2030
- Recent market entry into the Middle East, with plans to expand into additional international markets
- Regulatory approvals in Oman and China
- FDA approval process underway
- Committed to maintaining operational efficiency while scaling up production and clinical deployment

## Strong intellectual property protections

 Robust IP portfolio with several patents issued and pending, protecting core technologies through 2040

### Experienced leadership and advisory board

- Led by CEO Mark White, a pioneer in digital medical markets with direct experience in neuro-stimulation technologies
- Core executive team includes Dr. David Owens (CMO) and Marilyn Elson (CFO), who together bring decades of experience in medical technology, clinical operations, and financial management
- Supported by an advisory board with deep expertise in investment banking, global strategy, and product development

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations and subject to change. RedChip Companies and its affiliates may buy and sell shares of any investor. The information contained herein is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity (finduding but not limited to lost profits), loss of opportunities, trading losses and data offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity (finduding but not limited to lost profits), loss of opportunities, trading losses and damages that may arise out of the use of information provided to any person or entity (finduding but not limited to lost profits). The information, so do poptrunities, trading losses and damages that may rese curacy or information provided to any person or entity (including but not limited to lost profits). The information, so do poptrunities, trading losses and damages that may reset the particular investment heeds of any investor. The information on stock market investing is inherently risky. RedChip Companies is not response that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investor



# Nasdaq: NXL



## **Global Mental Health Epidemic**



#### Insomnia

Almost 40 million Americans suffer from chronic insomnia (NCBI). 40% of people with insomnia are believed to also be affected by a mental health disorder.

\*\*Nexalin Gen-1 devices obtained FDA clearance for Insomnia. In December 2019, FDA required new amended 510K applications for insomnia. Nexalin is presently analyzing prior FDA applications to determine new regulatory strategies for the treatment of Insomnia.



# **Value Proposition**

<u>9</u>

Anxiety

Anxiety disorders are common, affecting about 18 percent of adults. But only about a third seek treatment. (Anxiety and Depression Assoc. of America).

\*\*Nexalin Gen-1 devices obtained FDA clearance for Anxiety. In December 2019, FDA required new amended 510K applications for Anxiety. Nexalin is presently analyzing prior FDA applications to determine new regulatory strategies for the treatment of Anxiety.



#### Dementia and Depression

An estimated 6.2 million Americans aged 65 and older are living with Alzheimer's Dementia in 2021 (alz.org). Experts estimate that up to 40 percent of people with Alzheimer's disease suffer from significant depression. (Alzheimer's Assoc.)

\*\*\*Nexalin is in the planning process to submit applications for FDA clearance for the treatment of Depression and Mild Dementia Disorder.



#### Addiction

Approximately 20 million Americans battled some form of substance abuse each year, prior to the additional challenge of Covid-19. (NSDUH)

\*\*\* Nexalin is in the planning process to submit applications for FDA clearance for the treatment of Addiction and Substance Use Disorder.

Nexalin Technology stands at the forefront of the mental health treatment revolution with its cutting-edge, non-invasive neurostimulation technology. By focusing on deep brain stimulation, Nexalin's devices, particularly the advanced Gen-3 HALO<sup>™</sup> Clarity, offer a groundbreaking alternative to traditional pharmacological treatments. This technology has shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries—conditions that affect millions but have limited effective treatments—positioning Nexalin as an emerging leader in a market poised for substantial growth, projected to reach \$537 billion by 2030.

Recent strategic developments, such as the introduction of the Virtual Clinic, allow patients to receive treatment from the comfort of their homes, thereby enhancing Nexalin's market differentiation and patient accessibility. Combined with the robust expansion of the Company's intellectual property portfolio and regulatory approvals in multiple countries, these developments broaden Nexalin's market presence and are expected to drive sustained shareholder value improvement. Nexalin offers investors an opportunity to invest in a company that is not just prepared for the future but is actively shaping it, offering a profound chance to improve mental health outcomes on a global scale.

# **Global Funded Clinical Trials in Process**



RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip propris, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity (for the quality, accuracy, completeness, reliability or timeliness of the information provided to any person or entity (including but not limited to bis profiles, loss of opportunities, trading losses and damages that may arise out of the use of information provided to any person or entity (including but not limited to bis profiles, trading losses and damages that may result from any inaccuracy or incompleteness of apport. Companies is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investored making any investor. RedChip Comp